The first steps towards developing a vaccine against an insidious sexual transmitted infection (STI) have been accomplished by researchers at McMaster University.
Researchers at the Michael G. DeGroote Institute for Infectious Disease Research at McMaster have developed the first widely protective vaccine against chlamydia, a common STI that is mostly asymptomatic but impacts 113 million people around the world each year and can result in infertility.
In a study, recently published in the journal Vaccine, the researchers show that a novel chlamydial antigen known as BD584 is a potential vaccine candidate for the most common species of chlamydia known as Chlamydia trachomatis.
As most C. trachomatis infections are asymptomatic, chlamydia can often go untreated and lead to upper genital tract infections, pelvic inflammatory disease, and infertility. This is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.
“Vaccine development efforts in the past three decades have been unproductive and there is no vaccine approved for use in humans,” said Bulir, who just finished his PhD in medical sciences at McMaster.
“Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.”
In the research team’s study, BD584 was able to reduce chlamydial shedding – a symptom of C. trachomatis – by 95 per cent. The antigen also decreased hydrosalpinx, another C. trachomatis symptom which involves fallopian tubes being blocked with serous fluids, by 87.5 per cent.
The results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster’s Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton’s Research Institute where the work was performed.
Co-author and McMaster PhD student, Steven Liang, explains, “not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.”
Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.
“The vaccine would be administered through the nose. This is easy and painless and does not require highly trained health professionals to administer, and that makes it an inexpensive solution for developing nations,” he said.
The next step is more testing for effectiveness against different strains of Chlamydia and in different formulations. The study was funded by the Canadian Institutes for Health Research.
The Latest on: Chlamydia
via Google News
The Latest on: Chlamydia
- Yale study finds link between STIs and frackingon February 27, 2020 at 8:17 pm
Investigators found increased rates of chlamydia and gonorrhea in Texas counties during years of high drilling activity. Still, the study shows no statistically significant relationship between the ...
- Does having sex with many people affect anything?on February 27, 2020 at 7:19 am
These diseases usually don’t manifest immediately but only appear after a certain period of time. Does having sex with many people affect anything? Chlamydia: The disease is more common in women than ...
- Is It Too Soon to Predict an End to Cervical Cancer?on February 25, 2020 at 9:41 pm
It also protects against strains that cause genital warts. Initial figures in England are encouraging. Public Health England (PHE) has carried out HPV surveillance testing of women aged 16 to 24 ...
- STD Testing Devices Market Eyeing Remarkable Growth due to Increase in Lifestyle Deviceson February 25, 2020 at 2:06 am
Sexually transmitted diseases or STD are diseases that spread from sexual contacts. Human immunodeficiency virus, papilloma virus, herpes simplex virus, syphilis, chlamydia are the most common forms ...
- Chlamydia Infection Test Market 2020-2025 Productivity Data Analysis by Key Players Abbott, ADI/American Diagnostica, Agilent Technologieson February 20, 2020 at 5:19 am
Global Chlamydia Infection Test Market 2020-2025 research report is an in-depth analysis of the latest trends, market size, status, upcoming technologies, industry drivers, challenges with key company ...
- Chlamydia's covert reproductionon February 19, 2020 at 6:03 am
UF researchers have resolved a two-decade old mystery centered upon how the bacteria chlamydia divide and reproduce. Newly published results from the lab of Anthony Maurelli, a microbiologist in UF's ...
- Birmingham's Chlamydia hotspots revealed in shocking mapon February 18, 2020 at 5:06 am
The rate of chlamydia in the city was said to be 'significantly worse' than the England average. The worst areas in the city for Chlamydia diagnosis have been revealed in a shocking map - and the ...
- Sex ed? Best leave it to Chlamydia Cath...on February 18, 2020 at 4:08 am
In a scene reminiscent of an action thriller, I threw Chlamydia Cath into my classroom as if she were a grenade, and then ran away. I was asked not to stay as it might mean that the students wouldn’t ...
- Shale drilling activity linked to high rates of gonorrhea and chlamydia in Texason February 14, 2020 at 4:15 am
Researchers at the Yale School of Public Health have found that rates of two sexually transmitted infections (STIs), gonorrhea and chlamydia, are 15% and 10% higher, respectively, in Texas ...
- Meet the sex educator behind the chlamydia outbreak in 'Sex Education'on February 11, 2020 at 9:23 am
It's not everyday you get a WhatsApp voice note explaining how it's possible to get chlamydia in your eye. But that's what I received when talking to sex educator Alix Fox about her role as a ...
via Bing News